Investors & Media

2008 News and Events

Date Title   11/18/08 New Publication Shows Angiomax Significantly Reduces Initial Hospital Costs by $572 Per Patient Compared to Conventional Therapy in Moderate and High-Risk ACS Patients Prospective Economic Evaluation of Alternative Antithrombotic Strategies Published in the Journal of the American College of CardiologyPARSIPPANY, N.J., Nov 18, 2008 (BUSINESS WIRE) -- --Intended for U.S. Audiences Only The Medicines Company (NASDAQ: MDCO) announced that a prospective analysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage StrategY) trial showed that total hospital stay costs were lowest with Angiomax monotherapy (mea...  10/22/08 The Medicines Company Reports Third Quarter 2008 Financial Results PARSIPPANY, N.J.--(BUSINESS WIRE)-- The Medicines Company (NASDAQ: MDCO) today announced its financial results for the third quarter and first nine months of 2008. Highlights for the third quarter of 2008: -- Net revenue increased by 42% to $88.1 million for the third quarter of 2008 from $62.2 million for the third quarter of 2007. -- Angiomax(R) (bivalirudin) U.S. sales increased by 40% to $85.0 million for the third quarter of 2008 f...  10/21/08 Poor Perioperative Blood Pressure Control Linked to 30-Day Morbidity and Mortality in Cardiac Surgery Patients New Analysis from the ECLIPSE Trial ORLANDO, Fla.--(BUSINESS WIRE)-- FOR U.S. AUDIENCES ONLY The Medicines Company (NASDAQ: MDCO) today announced that poor blood pressure control during cardiac surgery is associated with a higher risk of 30-day death, stroke, myocardial infarction and renal dysfunction, compared to patients with tight blood pressure control, according to a post-hoc analysis of the ECLIPSE trial. The data were presented at the American Society of Anesthesiologists...  10/15/08 Angiomax(R) Reduced Cardiac Mortality by 43 Percent and Improved Overall Survival by 31 Percent at One-Year in HORIZONS-AMI Trial -- First Trial of Pharmacologic Therapy to Demonstrate a Mortality Benefit in STEMI Patients Undergoing Primary PCI -- WASHINGTON--(BUSINESS WIRE)-- The Medicines Company (NASDAQ: MDCO) today announced one-year follow-up data from the landmark HORIZONS-AMI trial demonstrated that Angiomax(R) (bivalirudin) significantly reduced cardiac-related death by 43 percent (p=0.005), improved overall survival by 31 percent (p=0.029) and reduced major bleeding complications by 39 percent (p less ...  10/14/08 The Medicines Company Announces HORIZONS-AMI 1-Year Data To Be Presented at 2008 TCT Meeting WASHINGTON--(BUSINESS WIRE)-- FOR U.S. AUDIENCES ONLY The Medicines Company (NASDAQ:MDCO) -- today announced that 1-year clinical data from the HORIZONS-AMI trial, comparing Angiomax(R) (bivalirudin) vs. unfractionated heparin (UFH) plus glycoprotein IIb/IIIa Inhibitors (GPI), will be presented in a late-breaker presentation on October 15, 2008 in a session that begins at 11 am at the 2008 Transcatheter Cardiovascular Therapeutics (TCT) Conference, which is being held f...  10/08/08 The Medicines Company to Announce Third Quarter 2008 Financial Results on Wednesday, October 22, 2008 Conference Call to be Held at 8:30 a.m. Eastern Time FOR IMMEDIATE RELEASE: PARSIPPANY, N.J.--(BUSINESS WIRE)-- The Medicines Company (NASDAQ: MDCO) has scheduled its quarterly conference call for Wednesday, October 22, 2008 at 8:30 a.m. Eastern Time to discuss third quarter 2008 financial results and operational developments. The conference call will be available via phone and webcast. The dial in information is listed below: Domestic Dial In: 877-719-9795 Internati...  10/03/08 New Publication Shows Cleviprex(TM) Provides More Precise Blood Pressure Control in Cardiac Surgery Patients ECLIPSE Data Published in Anesthesia and Analgesia PARSIPPANY, N.J.--(BUSINESS WIRE)-- The Medicines Company (NASDAQ: MDCO) today announced that ECLIPSE, the largest safety program to date comparing intravenous antihypertensive therapies, has been published in the October issue of Anesthesia and Analgesia. Results show Cleviprex(TM) (clevidipine butyrate) injectable emulsion is safe and effective for managing blood pressure in patients undergoing cardiac surgery and provides more pre...  09/03/08 New Analysis From HORIZONS-AMI Shows Major Bleeding Has a Significant Impact and Contributes to 30-Day Mortality Following Angioplasty in Severe Heart Attack Patients Data presented at the 2008 European Society of Cardiology Annual Meeting For Immediate Release in the United States PARSIPPANY, N.J.--(BUSINESS WIRE)--Sept. 3, 2008--The Medicines Company (NASDAQ:MDCO) today announced the presentation of a new analysis of data from the HORIZONS-AMI trial demonstrating that major bleeding contributes to more deaths at 30 days than repeat heart attack, or re-infarction, in severe heart attack patie...  08/26/08 ACUITY 1-Year Sub-Analysis Published in Journal of the American College of Cardiology New publication shows treatment with Angiomax provides similar protection from ischemic events and death at 1-year, while reducing bleeding at 30 days, compared to standard therapy in moderate- and high- risk ACS patients undergoing PCI FOR IMMEDIATE RELEASE IN THE UNITED STATES PARSIPPANY, N.J.--(BUSINESS WIRE)--Aug. 26, 2008--The Medicines Company (NASDAQ: MDCO) announced that a sub-analysis of the ACUITY (Acute Catheterization and Urgent Interventi...  08/26/08 New Publication Shows Cleviprex(TM) is Safe and Effective for Treatment of Acute, Severe Hypertension VELOCITY Trial Published in Annals of Emergency Medicine PARSIPPANY, N.J.--(BUSINESS WIRE)--Aug. 26, 2008--The Medicines Company (NASDAQ: MDCO) today announced that the results of VELOCITY, a pivotal Phase 3 safety and efficacy trial of its new intravenous (IV) therapy Cleviprex(TM) (clevidipine butyrate) injectable emulsion, were published in the August issue of the Annals of Emergency Medicine. The clinical trial demonstrated that Cleviprex is safe and effective for the treatmen...  08/05/08 The Medicines Company Acquires CU-2010 and Curacyte Discovery GmbH PARSIPPANY, N.J.--(BUSINESS WIRE)--Aug. 5, 2008--The Medicines Company (NASDAQ: MDCO) today announced that it has acquired German-based Curacyte Discovery GmbH and its lead compound, CU-2010, which is being developed for the prevention of surgical blood loss. CU-2010 is a small molecule serine protease inhibitor. In preclinical studies, the compound has demonstrated a favorable pharmacokinetic profile for the surgical setting with a rapid onset and offset of effect, due to its sho...  08/04/08 The Medicines Company's Cleviprex(TM) Receives FDA Approval First New IV Antihypertensive Treatment Approved in Ten Years FOR U.S. AUDIENCES ONLY PARSIPPANY, N.J.--(BUSINESS WIRE)--Aug. 4, 2008--The Medicines Company (NASDAQ: MDCO) announced today that the U.S. Food and Drug Administration (FDA) has approved the intravenous (IV) therapy Cleviprex(TM) (clevidipine butyrate) injectable emulsion for the reduction of blood pressure when oral therapy is not feasible or not desirable. Cleviprex, a novel IV antihypertensive, repres...  07/23/08 The Medicines Company Reports Second Quarter and First Half 2008 Financial Results and Raises Full Year Top Line Guidance PARSIPPANY, N.J.--(BUSINESS WIRE)--July 23, 2008--The Medicines Company (NASDAQ: MDCO) today announced its financial results for the second quarter and first half of 2008. Financial highlights for the second quarter of 2008: -- Net revenue increased by 54% to $86.7 million for the second quarter of 2008 from $56.4 million for the second quarter of 2007. -- Angiomax(R) (bivalirudin) U.S. sales increased by 53% to $84.5 million for th...  07/14/08 New Publication Shows Cleviprex(TM) is Effective for Rapid Treatment of Acute Hypertension After Cardiac Surgery ESCAPE-2 Trial Published in Journal of Anesthesia and Analgesia FOR U.S. AUDIENCES ONLY PARSIPPANY, N.J.--(BUSINESS WIRE)--July 14, 2008--The Medicines Company (NASDAQ: MDCO) today announced that the results of ESCAPE -2, a pivotal Phase 3 efficacy trial of its investigational agent Cleviprex(TM) (clevidipine butyrate) injectable emulsion, were published in the July issue of the journal Anesthesia and Analgesia. The clinical trial demonstrated that Cleviprex is effective...  07/09/08 The Medicines Company to Announce Second Quarter 2008 Financial Results on Wednesday, July 23, 2008 Conference Call to be Held at 8:30 a.m. Eastern TimePARSIPPANY, N.J., Jul 09, 2008 (BUSINESS WIRE) -- The Medicines Company (NASDAQ: MDCO) has scheduled its quarterly conference call for Wednesday, July 23, 2008 at 8:30 a.m. Eastern Time to discuss second quarter 2008 financial results, guidance and operational developments. The conference call will be available via phone and webcast. The dial in information is listed below: Domestic Dial In: 877-419-6590 International Dial In: 719-32...  06/20/08 Controlling Perioperative Hypertension with Cleviprex Reduces Risk of Heart Attack and of Death Following Cardiac Surgery, According to New Analyses Post-Hoc Analyses from ECLIPSE Trial Presented at SCA Meeting VANCOUVER, British Columbia--(BUSINESS WIRE)--June 20, 2008--The Medicines Company (NASDAQ: MDCO) today announced that data from two post-hoc analyses of the ECLIPSE trial showed that use of Cleviprex(TM) (clevidipine butyrate) injectable emulsion to control blood pressure during cardiac surgery may be associated with a reduced risk of heart attack compared to two of three currently used IV antihypertensive agents. In a...  06/17/08 The Medicines Company Hires Glyn R. Parkin as Senior Vice President, International Operations PARSIPPANY, N.J., Jun 17, 2008 (BUSINESS WIRE) -- The Medicines Company (NASDAQ: MDCO) today announced that Glyn R. Parkin has joined the Company as Senior Vice President, International Operations. Working with other senior leaders of the Company, Parkin will be responsible for the design, implementation and leadership of the international organization. He will be responsible for the establishment of functioning, capable organizations and business operations in new territories, and then tr...  06/05/08 The Medicines Company to Participate in the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference PARSIPPANY, N.J., Jun 05, 2008 (BUSINESS WIRE) -- The Medicines Company (NASDAQ: MDCO) is scheduled to present at The Seventh Annual Needham Biotechnology and Medical Technology Conference on June 12th, at 3:00pm Eastern Time. A company overview and outlook will be provided in the presentation. The session will be webcast with a link available at The Medicines Company's website: http://www.themedicinescompany.com. MDCO-G About The Medicines Company The Medicines Company (NASDAQ: MD...  06/03/08 The Medicines Company Announces Option Grants under NASDAQ Marketplace Rule 4350 PARSIPPANY, N.J., Jun 03, 2008 (BUSINESS WIRE) -- The Medicines Company (NASDAQ: MDCO) announced today that in accordance with NASDAQ Marketplace Rule 4350, the Company issued new inducement stock options to three executive and non-executive new hires due to additional hiring primarily in connection with its expansion in both Europe and the U.S. The inducement stock options cover an aggregate of 54,500 shares of common stock and are classified as non-qualified stock options with an exerci...  05/29/08 Cleviprex(TM) Reduces and Controls Acutely Elevated Blood Pressure in Elderly Patients, According to New Analysis from VELOCITY Trial Over 96 Percent of Patients Reached Target Blood Pressure within 30 Minutes INTENDED FOR US AUDIENCES ONLY WASHINGTON--(BUSINESS WIRE)--May 29, 2008--The Medicines Company (NASDAQ: MDCO) today announced that its investigational agent, Cleviprex(TM) (clevidipine butyrate) injectable emulsion was well tolerated in elderly patients and rapidly achieved and maintained blood pressure control in patients presenting to the emergency department or ...  05/28/08 The Medicines Company Receives FDA Review Letter for Angiomax Supplemental Filing PARSIPPANY, N.J., May 28, 2008 (BUSINESS WIRE) -- The Medicines Company (NASDAQ: MDCO) announced receipt of a not approvable letter from the U.S. Food and Drug Administration (FDA) on a supplemental New Drug Application (sNDA) for an additional dosing regimen for Angiomax(R) (bivalirudin) in the treatment of acute coronary syndromes (ACS) initiated in the emergency department. The primary basis of the filing was the ACUITY trial, whose results have been published in New England Journal of ...  05/22/08 Results Published in New England Journal of Medicine Show Angiomax Improved Net Clinical Outcomes and Resulted in Improved Survival Rates in the Most Severe Heart Attack Patients -- HORIZONS-AMI One of the Largest Primary PCI Trials Ever -- INTENDED FOR US AUDIENCES ONLY PARSIPPANY, N.J.--(BUSINESS WIRE)--May 22, 2008--The Medicines Company (NASDAQ: MDCO) today announced that the New England Journal of Medicine published results from the HORIZONS-AMI trial. According to findings, Angiomax(R) (bivalirudin) significantly improved net clinical adverse events by 24 percent as well as resulted in a reduction in overall mortality by 32 percent and card...  05/15/08 The Medicines Company Announces Option Grants under NASDAQ Marketplace Rule 4350 PARSIPPANY, N.J.--(BUSINESS WIRE)--May 15, 2008--The Medicines Company (NASDAQ: MDCO) announced today that in accordance with NASDAQ Marketplace Rule 4350, the Company issued new inducement stock options to four executive and non-executive new hires due to additional hiring primarily in connection with its expansion in both Europe and the U.S. The inducement stock options cover an aggregate of 43,000 shares of common stock and are classified as non-qualified stock options with an ...  05/05/08 Results Published in JACC Show Clinical Advantage of Switching to Angiomax from Heparin in Acute Coronary Syndrome Patients Undergoing Early Invasive Treatment PARSIPPANY, N.J.--(BUSINESS WIRE)--May 5, 2008--The Medicines Company (NASDAQ: MDCO) today announced that the Journal of the American College of Cardiology published a new subgroup analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial demonstrating that switching to Angiomax(R) (bivalirudin) after pre-treatment with heparin (UFH or enoxaparin) results in comparable ischemic outcomes and approximately 50 percent reduction in major bleeding compa...  04/30/08 The Medicines Company Announces Option Grants under NASDAQ Marketplace Rule 4350 PARSIPPANY, N.J.--(BUSINESS WIRE)--April 30, 2008--The Medicines Company (NASDAQ: MDCO) announced today that in accordance with NASDAQ Marketplace Rule 4350, the Company issued new inducement stock options to two executive and non-executive new hires due to additional hiring primarily in connection with its expansion in both Europe and the U.S. The inducement stock options cover an aggregate of 13,000 shares of common stock and are classified as non-qualified stock options with an...  04/23/08 The Medicines Company Reports First Quarter 2008 Financial Results PARSIPPANY, N.J.--(BUSINESS WIRE)--April 23, 2008--The Medicines Company (NASDAQ: MDCO) today announced its financial results for the first quarter of 2008. Financial highlights for the first quarter of 2008: -- Net revenue increased by 19% to $79.4 million for the first quarter of 2008 from $66.6 million for the first quarter of 2007. -- Angiomax(R) (bivalirudin) U.S. sales increased by 16% to $76.9 million for the first quarter of 20...  04/15/08 The Medicines Company Announces Option Grants Under NASDAQ Marketplace Rule 4350 PARSIPPANY, N.J., Apr 15, 2008 (BUSINESS WIRE) -- The Medicines Company (NASDAQ: MDCO) announced today that in accordance with NASDAQ Marketplace Rule 4350, the Company issued new inducement stock options to fourteen executive and non-executive new hires due to additional hiring primarily in connection with its expansion in both Europe and the U.S. The inducement stock options cover an aggregate of 166,900 shares of common stock and are classified as non-qualified stock options with an ex...  04/09/08 The Medicines Company to Announce First Quarter 2008 Financial Results on Wednesday, April 23, 2008 Conference Call to be Held at 8:30 a.m. Eastern TimePARSIPPANY, N.J., Apr 09, 2008 (BUSINESS WIRE) -- The Medicines Company (NASDAQ: MDCO) has scheduled its quarterly conference call for Wednesday, April 23, 2008 at 8:30 a.m. Eastern Time to discuss first quarter 2008 financial results and operational developments. The conference call will be available via phone and webcast. The dial in information is listed below: Domestic Dial In: 877-548-7901 International Dial In: 719-325-4900 ...  03/29/08 Angiomax Demonstrated Improved Outcomes in Acute Heart Attack Patients Undergoing Primary Angioplasty Independent of Individual Risk Factors New Findings from HORIZONS-AMI Trial Consistent with Overall Results CHICAGO--(BUSINESS WIRE)--March 29, 2008--The Medicines Company (Nasdaq: MDCO) today announced that Angiomax(R) (bivalirudin) resulted in improved net adverse clinical outcomes and reduced the risk of major bleeding despite the sex, age, diabetes status or renal function of heart attack patients in the HORIZONS-AMI trial compared to a more complex treatment regimen 30 days followin...  03/14/08 The Medicines Company Announces Option Grants under NASDAQ Marketplace Rule 4350 PARSIPPANY, N.J.--(BUSINESS WIRE)--March 14, 2008--The Medicines Company (NASDAQ: MDCO) announced today that in accordance with NASDAQ Marketplace Rule 4350, the Company issued new inducement stock options to four executive and non-executive new hires due to additional hiring primarily in connection with its expansion in both Europe and the U.S. The inducement stock options cover an aggregate of 88,000 shares of common stock and are classified as non-qualified stock options with a...  02/15/08 The Medicines Company Announces Option Grants under NASDAQ Marketplace Rule 4350 PARSIPPANY, N.J.--(BUSINESS WIRE)--Feb. 15, 2008--The Medicines Company (NASDAQ: MDCO) announced today that in accordance with NASDAQ Marketplace Rule 4350, the Company issued new inducement stock options to sixteen executive and non-executive new hires due to additional hiring primarily in connection with its expansion in both Europe and the U.S. The inducement stock options cover an aggregate of 245,000 shares of common stock and are classified as non-qualified stock options wit...  02/13/08 The Medicines Company Reports Full Year and Fourth Quarter 2007 Financial Results PARSIPPANY, N.J.--(BUSINESS WIRE)--Feb. 13, 2008--The Medicines Company (NASDAQ: MDCO) today announced its financial results for the full year and fourth quarter of 2007. Financial highlights for the full year of 2007: -- Net revenue increased by 20% to $257.5 million for 2007 from $214.0 million for 2006. -- Angiomax(R) (bivalirudin) U.S. sales increased by 27% to $255.0 million for 2007 from $200.7 million for 2006. -- Angiomax/Angiox interna...  02/05/08 Cleviprex(TM) Demonstrated Rapid, Precise Blood Pressure Control in High-Risk Patients, According to New Analyses Over 90 Percent of Patients Reached and Maintained Target Blood Pressure In Both Renal Dysfunction and Heart Failure Groups HONOLULU--(BUSINESS WIRE)--Feb. 5, 2008--The Medicines Company (NASDAQ: MDCO) announced today that its investigational agent, Cleviprex(TM) (clevidipine butyrate injectable emulsion), rapidly achieved and maintained blood pressure control in patients with renal dysfunction (RD) and patients with acute heart failure (AHF), according to two new analyses f...  02/04/08 Steven Steinhubl, MD, Joins The Medicines Company as Global Vice President, Thrombosis PARSIPPANY, N.J.--(BUSINESS WIRE)--Feb. 4, 2008--The Medicines Company (NASDAQ: MDCO) today announced that Dr. Steven Steinhubl has joined the Company as Global Vice President, Thrombosis. Dr. Steinhubl will be responsible for the development programs for both cangrelor, an investigational antiplatelet agent, and Angiox(R) (bivalirudin) from the Company's European headquarters in Zurich, Switzerland. His appointment marks the Company's first global leadership position based outside of...  02/01/08 The Medicines Company Announces Multiple Presentations at Upcoming Society of Critical Care Medicine (SCCM) Annual Meeting PARSIPPANY PARSIPPANY, N.J.--(BUSINESS WIRE)--Feb. 1, 2008--The Medicines Company (NASDAQ: MDCO) today announced that five select abstracts associated with the treatment of acutely elevated blood pressure will be presented at the 37th Critical Care Conference of the Society of Critical Care Medicine (SCCM), February 2 - 6, 2008, at the Hawaii Convention Center in Honolulu, Hawaii. Poster Details: ---------------------------------------------------------------------- Sunday, Febru...  01/30/08 The Medicines Company to Announce Fourth Quarter and Full Year 2007 Financial Results on Wednesday, February 13, 2008 Conference Call to be Held at 8:30 a.m. Eastern TimePARSIPPANY, N.J., Jan 30, 2008 (BUSINESS WIRE) -- The Medicines Company (NASDAQ: MDCO) has scheduled its quarterly conference call for Wednesday, February 13, 2008 at 8:30 a.m. Eastern Time to discuss fourth quarter and full year 2007 financial results, operational developments and outlook for 2008. The conference call will be available via phone and webcast. The dial in information is listed below: Domestic Dial In: 877-397-029...  01/29/08 The Medicines Company's Angiox(R) Receives European Authorization for Expanded Use in Patients with Acute Coronary Syndromes (ACS) PARSIPPANY, N.J.--(BUSINESS WIRE)--Jan. 29, 2008--The Medicines Company (NASDAQ: MDCO) today announced the receipt of the European Commission Decision authorizing an expanded use for Angiox(R) (bivalirudin) in adult patients with acute coronary syndromes (ACS), specifically patients with unstable angina (UA) or non-ST segment elevation myocardial infarction (NSTEMI) planned for urgent or early intervention, when used with aspirin and clopidogrel. "With this new indication, Angiox ...  01/16/08 The Medicines Company Announces Option Grants Under NASDAQ Marketplace Rule 4350 PARSIPPANY, N.J.--(BUSINESS WIRE)--Jan. 16, 2008--The Medicines Company (NASDAQ: MDCO) announced today that in accordance with NASDAQ Marketplace Rule 4350, the Company issued new inducement stock options to five executive and non-executive new hires due to additional hiring primarily in connection with its expansion in both Europe and the U.S. The inducement stock options cover an aggregate of 88,000 shares of common stock and are classified as non-qualified stock options with an...  01/07/08 James Ferguson, MD Joins The Medicines Company as Vice President, Global Medical, Surgical and Critical Care PARSIPPANY, N.J.--(BUSINESS WIRE)--Jan. 7, 2008--The Medicines Company (NASDAQ:MDCO) today announced that Dr. James Ferguson has joined the Company as Vice President, Global Medical, Surgical and Critical Care. Dr. Ferguson's first charge will be leading medical science/affairs strategies and activities supporting the Company's anticipated launch of Cleviprex(TM) (clevidipine butyrate injectable emulsion), a novel investigational IV antihypertensive. "I am thrilled to be joining t...